CN106511544A - Composition for reducing blood glucose and application of composition - Google Patents
Composition for reducing blood glucose and application of composition Download PDFInfo
- Publication number
- CN106511544A CN106511544A CN201611108062.XA CN201611108062A CN106511544A CN 106511544 A CN106511544 A CN 106511544A CN 201611108062 A CN201611108062 A CN 201611108062A CN 106511544 A CN106511544 A CN 106511544A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- blood sugar
- mulberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 118
- 210000004369 blood Anatomy 0.000 title claims abstract description 118
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 239000008103 glucose Substances 0.000 title abstract description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 103
- 241000533293 Sesbania emerus Species 0.000 claims abstract description 49
- 229940069765 bean extract Drugs 0.000 claims abstract description 47
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 26
- 235000000346 sugar Nutrition 0.000 claims description 104
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 49
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 49
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims description 49
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 38
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 10
- 235000013824 polyphenols Nutrition 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- -1 D-mannital Substances 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000000905 isomalt Substances 0.000 claims description 3
- 235000010439 isomalt Nutrition 0.000 claims description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 210000001217 buttock Anatomy 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 18
- 240000000249 Morus alba Species 0.000 abstract description 11
- 235000008708 Morus alba Nutrition 0.000 abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 235000001497 healthy food Nutrition 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 235000020230 cinnamon extract Nutrition 0.000 abstract 2
- 230000000291 postprandial effect Effects 0.000 description 77
- 230000000052 comparative effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 150000008163 sugars Chemical class 0.000 description 13
- 238000010200 validation analysis Methods 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 9
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 9
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 9
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 9
- 229940074393 chlorogenic acid Drugs 0.000 description 9
- 235000001368 chlorogenic acid Nutrition 0.000 description 9
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 9
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 9
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 238000013103 analytical ultracentrifugation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 2
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 2
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 2
- 108010001483 Glycogen Synthase Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000021258 carbohydrate absorption Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000522254 Cassia Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- OZKRURPNXOGYGD-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1 OZKRURPNXOGYGD-UHFFFAOYSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to the field of healthy food, and relates to a composition for reducing blood glucose and application of the composition. The composition is mainly prepared from, by weight, 10-50 parts of mulberry leaf extract, 1-30 parts of cinnamon extract and 5-60 parts of green coffee bean extract. According to the composition for reducing blood glucose, the mulberry leaf extract, the cinnamon extract and the green coffee bean extract are used as effective raw materials, the three components are reasonable in compatibility, achieve the synergistic effect and are reasonably matched with an excipient, and therefore the edible medicine for effectively reducing blood glucose can be prepared. Taking compliance of diabetic patients is improved, and the medicine taking pain is reduced.
Description
Technical field
The invention belongs to healthy food field, is related to a kind of hypoglycemic composition of drop and its application, and in particular to a kind of
Improve IGT and reduce composition and its application of type-II diabetes blood sugar.
Background technology
Type-II diabetes are that a kind of glycolipid metabolism caused due to insulin secretion relative deficiency or insulin resistance is chaotic
Syndrome.Diabetes criterion：Fasting blood-glucose >=6.1mmol/L, postprandial blood sugar >=11.1mmol/L.2 hours blood glucose after the meal,
More than normal 7.8mmol/L, but still not up to 11.1mmol/L or fasting blood-glucose claim IGT between 6.2～7.0.
Such case can be described as a kind of transient state of normal person to diabetes, although this groups of people is not also diabetes now,
It is that generation diabetes B is dangerous very high in the future, it may be said that be the reserves of diabetes.
According to relevant research, as annual 5-8%, patient will develop into type-II diabetes.IGT crowd
OHA is not typically needed, but is often difficult to accomplish good habits and customs, OHA is necessarily to psychology and life
Reason brings adverse effect, so the food of effective control blood sugar becomes the demand of such crowd.
IGT is the stage that each diabetic necessarily experiences, and is diagnosed as diabetic, and the initial stage needs mouth
A type antidiabetic drug is taken, glycemic control is undesirable or blood sugar is persistently raised, patient needs oral various different pharmacological action drops
Sugared medicine or insulin injection.For example：Diabetes patient's medication ranks the first medicine Acarbose, and pharmacological action mainly blocks starch
Enzyme, slows down carbohydrate absorption to reduce blood sugar.Sulfonylurea drugs, pharmacological action mainly stimulate insulin secretion,
Increase internal insulin level to reduce blood sugar.Melbine class medicine, pharmacological action predominantly mitigate insulin resistance, promote
Utilization of the peripheral tissues to glucose, suppresses glycogen output to reduce blood sugar.All there is one-sidedness in three kinds of medicines, therapeutic effect is not
It is good, be not suitable for long-term taking.
105616958 A of CN disclose a kind of hypoglycemic composition, hypoglycemia healthcare food and preparation method thereof and answer
With the active ingredient of the composition is mulberry-leaf extract, Astragalus Root P.E, Rhizoma Polygonati extract, kudzu root extract, pyridine carboxylic acid
Chromium, oligosaccharide and L-arabinose, but used as a kind of reduction hypoglycemic medicament of consumption, its effect is not obvious.
104082742 A of CN disclose a kind of functional food of conditioning blood sugar balance, and the food is by following parts by weight
Raw material make：Mulberry-leaf extract 30-50 parts, cinnamomum cassia extract 30-50 parts, vitamin C 5-10 parts, vitamin E 5-10 parts.Should
Functional food can reduce blood sugar under the cooperation of mulberry-leaf extract and cinnamomum cassia extract, but the medicine can only be from therein
Two aspect blood glucose rise always, effect are general.
Therefore a kind of functional food of three kinds of pharmacological actions of summary is developed, IGT crowd can be effectively reduced
While, more efficient reduction diabetes blood glucose, while reducing type-II diabetes crowd's several types antidiabetic drug while clothes
Burden.
The content of the invention
For the deficiencies in the prior art, it is an object of the invention to provide a kind of hypoglycemic composition of drop and its application,
The composition introduces mulberry-leaf extract, three kinds of components of cinnamomum cassia extract and green coffee bean extract and mutually promotes, and collaboration is made
With, greatly strengthen and drop hypoglycemic effect, and no toxic and side effect, blood sugar can be reduced as a kind of food medicine, had
Effect management blood sugar.
It is that, up to this purpose, the present invention is employed the following technical solutions：
On the one hand, the present invention provides a kind of drop hypoglycemic composition, the composition mainly include by weight as
Lower component：Mulberry-leaf extract 8-50 parts, cinnamomum cassia extract 1-30 parts and green coffee bean extract 5-60 parts.
In the present invention, mulberry-leaf extract Reverse transcriptase alpha-glucosidase hinders carbohydrate absorption, delays blood sugar to rise；
Green coffee bean extract G-6-Pase system is played a significant role during balance blood sugar regulates and controls in vivo, and suppression glucose-
The hepatic excretion that 6- phosphoric acid displacement enzymes can reduce adult-onset diabetes is too fast, by suppressing decomposition of glycogen and sugar different
It is raw, the formation of endogenous glucose is reduced, blood sugar is effectively reduced, maintains blood sugar steady；Cinnamomum cassia extract is promoting Glycogen synthesis
And have similar insulin action during Glycogen synthase activity, as insulin signaling, activate exhaustion insulin receptor, thorn
Sharp insulin receptor self phosphorylation, promotes glucose absorption, glycogen biosynthesis, activates Glycogensynthase.Carry in Chinese cassia tree
The compound Caffeic acid (DHH105) for taking purifying can increase the content of target tissue GLUT4, increase insulin sensitivity
Property.GLUT4 major functions are responsible for making glucose intake increase sharply under the conditions of insulin increases, to maintaining blood sugar homeostasis to have
Important function.By mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract are combined in the present invention, San Zhexiang
Mutually promote, three has played synergistic function, and the respective effect of three is also improved, and greatly strengthen composition
Hypoglycemic effect, it is possible to obtain hypoglycemic composition and food medicine.
The parts by weight of the mulberry-leaf extract are 8-50 parts, can for example be 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13
Part, 15 parts, 16 parts, 18 parts, 20 parts, 21 parts, 23 parts, 25 parts, 26 parts, 28 parts, 30 parts, 31 parts, 33 parts, 35 parts, 38 parts, 40
Part, 41 parts, 42 parts, 43 parts, 45 parts, 48 parts or 50 parts, preferably 20-45 parts, more preferably 30-40 parts, and above-mentioned
Concrete point value between numerical value, as space is limited and for simple and clear consideration, the present invention no longer scope described in exclusive list includes
Concrete point value.
The parts by weight of the cinnamomum cassia extract are 1-30 parts, can for example be 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7
Part, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts,
23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts or 30 parts, preferably 5-25 parts, more preferably 10-20 parts, with
And the concrete point value between above-mentioned numerical value, as space is limited and for simple and clear consideration, scope no longer described in exclusive list of the invention
Including concrete point value.
The parts by weight of the green coffee bean extract are 5-60 parts, can for example be 5 parts, 6 parts, 7 parts, 8 parts, 10 parts,
12 parts, 13 parts, 15 parts, 16 parts, 18 parts, 20 parts, 21 parts, 23 parts, 25 parts, 26 parts, 28 parts, 30 parts, 31 parts, 33 parts, 35 parts, 38
Part, 40 parts, 42 parts, 45 parts, 46 parts, 48 parts, 50 parts, 51 parts, 53 parts, 55 parts, 56 parts, 58 parts or 60 parts, preferably 15-58
Part, the concrete point value more preferably between 20-50 parts, and above-mentioned numerical value, as space is limited and for simple and clear consideration, this
The concrete point value that scope described in invention no longer exclusive list includes.
The mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is (3-8):(1-5):(5-
15) can for example be, 3:1:5、3:1:6、3:1:7、3:1:8、3:1:10、3:1:12、3:1:15、3:2:5、4:2:6、4:2:7、
4:2:8、4:2:10、4:2:12、3:2:15、5:3:5、5:3:6、5:3:7、3:3:8、3:3:10、6:3:12、6:3:15、6:4:
5、6:4:6、6:4:7、7:4:8、7:4:10、7:4:12、7:4:15、8:5:5、8:5:6、8:5:7、8:5:8、8:5:10、3:5:
12 or 8:5:15, preferably (4-6):(2-4):(6-10) the concrete point value, and between above-mentioned numerical value, as space is limited and for
Simple and clear consideration, the present invention concrete point value that no longer scope described in exclusive list includes.
Inventors be surprised to learn that, the mass ratio of mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is adjusted to
(4-6):(2-4):(6-10) when, which can further improve the hypoglycemic effect of said composition, these three components under this ratio
Mutually promote, cooperate, also improve the synergy of three.
In the present invention, the mass ratio of mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is preferably (4-6):(2-
4):(6-10), under the ratio, this three's material can farthest play synergy each other so as to respective effect
Further lifted, while hypoglycemic effect is lifted, can also effectively manage blood sugar.
According to the present invention, all materials containing 1-DNJ are all feasible, preferred mulberry-leaf extracts, mulberry leaf
Extract is the 1-DNJ of the only naturally plant origin, belongs to integration of drinking and medicinal herbs food, relative to chemical synthesis class
Speech, without lesions of liver and kidney, long-term taking will not cause hypoglycemia complication.In the mulberry-leaf extract, 1-DNJ contains
Measure as 0.5-30%, can for example be 0.5%, 0.6%, 0.8%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%th, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%,
25%th, 26%, 27%, 28%, 29% or 30%, the concrete point value between preferably 1-10%, and above-mentioned numerical value is limited to a piece
Width and for simple and clear consideration, the present invention concrete point value that no longer scope described in exclusive list includes.
According to the present invention, all materials containing Polyphenols are all feasible, preferred cinnamomum cassia extracts, and cinnamomum cassia extract is
In traditional Chinese medicine, one of polyphenols with blood sugar reducing function, and approved which has blood sugar reducing function by modern medicine
Material.In the cinnamomum cassia extract, the content of polyphenols is 1-80%, can for example be 1%, 2%, 3%, 5%, 8%,
10%th, 12%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or
80%, the concrete point value between preferably 10-70%, and above-mentioned numerical value, as space is limited and for simple and clear consideration, the present invention
The concrete point value that no longer scope described in exclusive list includes.
According to the present invention, all materials containing chlorogenic acid are all feasible, preferred green coffee bean extracts, green coffee bean
Extract Content of Chlorogenic Acid has the characteristic of targeted inhibition G-6-Pase.The green coffee bean extract Content of Chlorogenic Acid
Content is 10-80%, can for example be 10%, 12%, 15%, 20%, 22%, 25%, 30%, 32%, 35%, 40%,
42%th, 45%, 50%, 52%, 55%, 60%, 62%, 65%, 70%, 72%, 75% or 80%, preferably 20-70%, with
And the concrete point value between above-mentioned numerical value, as space is limited and for simple and clear consideration, scope no longer described in exclusive list of the invention
Including concrete point value.
Composition of the invention, in addition to mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract, may be used also
To contain other components, for example, can contain various excipient, the composition also includes excipient, can also contain this area
Known additive, such as stabilizer, flavoring agent etc., these components be according to those skilled in the art according to actual needs and
Particular determination is not done in the addition for carrying out, here.
Preferably, the excipient be filler, lubricant, disintegrant, colouring agent or flavouring in any one or
At least two mixture.
Preferably, the excipient be xylitol, D-sorbite, isomalt, D-mannital, starch, dextrin,
Microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropyl methyl cellulose, pulullan polysaccharide, talcum powder, superfine silica gel powder, stearic acid
In magnesium, calcium stearate or ethanol any one or at least two mixing.
Preferably, the parts by weight of the excipient account for 5-100 parts of the composition, preferably 10-80 parts.
The third aspect, the present invention provide a kind of drop hypoglycemic medicine, and the medicine includes the combination described in first aspect
Thing.
Preferably, the formulation of the medicine is any one in tablet, capsule or granule or at least two group
Close.
Fourth aspect, the present invention provide a kind of hypoglycemic composition of drop as described in relation to the first aspect or such as second aspect institute
The hypoglycemic medicine of drop stated is used to improve IGT.
In terms of 5th, the present invention provides a kind of hypoglycemic composition of drop as described in relation to the first aspect or such as second aspect institute
The hypoglycemic medicine of drop stated is used to treat type-II diabetes
Relative to prior art, the invention has the advantages that：
(1) the hypoglycemic composition of present invention drop is with mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract as work(
Effect raw material, three kinds of component scientific compatibilities, synergy, reasonably combined excipient can be prepared into and effectively reduce postprandial blood sugar
Consumption medicine, improve diabetic takes compliance, reduces the pain of medication, effectively improves sugar tolerance different
Often patient, can be used to treat type-II diabetes；
(2) present composition drops hypoglycemic effect substantially, and more than 30% patient takes after this composition blood after the meal
Sugared substantially to reduce, effectively, this composition drop the efficient of postprandial blood sugar reaches more than 40.5% patient's drop postprandial blood sugar
More than 70.5%.
Specific embodiment
Technical scheme is further illustrated below by specific embodiment.Those skilled in the art should be bright
, the embodiment be only to aid in understand the present invention, be not construed as to the present invention concrete restriction.
Unreceipted particular technique or condition person in embodiment, according to technology or condition described by document in the art,
Or carry out according to product description.Agents useful for same or the unreceipted production firm person of instrument, being can be by commercially available from regular channel
The conventional products of acquisition.
Embodiment 1
(1) prepare the composition for reducing postprandial blood sugar：
In the present embodiment, the composition for reducing postprandial blood sugar mainly includes following component by weight percentage：
30 parts of 35 parts of mulberry-leaf extract, 14 parts of cinnamomum cassia extract, 49 parts of green coffee bean extract and excipient；
Wherein, the mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is 5:2:7, the mulberry
In leaf extract, the content of 1-DNJ is 8%, and in the cinnamomum cassia extract, the content of polyphenols is 45%, institute
The content for stating green coffee bean extract Content of Chlorogenic Acid is 38%, and the excipient is xylitol, D-sorbite and isomaltoketose
Alcohol.
(2) efficacy validation：
IGT crowd：Patient 60, the wherein male sex 25, women 25, age distribution is 30-50 year.
Instructions of taking：Three times a day, every time 2, before the meal half an hour take, staple food amount male sex 200g, women 150g；Take 1
Individual month, monitor 1 time weekly.
Experimental group:The composition of postprandial blood sugar is reduced in edible the present embodiment, three times a day, 2 every time, half an hour before the meal
Take, staple food amount male sex 200g, women 150g；
Placebo, three times a day, 2 every time, take before the meal by half an hour for placebo, staple food amount male sex 200g, women
150g；Placebo is excipient in the present embodiment.
Take 1 month, monitor 2 times weekly, 1 experimental group, 1 placebo.
Efficacy assessments standard：According to《Health food is checked and assessment technique enforcement of regulations handbook》Newest revised correlation
Regulation：0th, 0.5,2 hours postprandial blood sugar TG-AUCs reduce statistically significant (reduced rate >=10%), judge the test sample
Product sugar tolerance index result is positive, and the given the test agent has the effect of auxiliary hyperglycemic.
By the validity Further Division of product, then it is divided into significant curative effect：Postprandial blood sugar TG-AUC reduced rate >=
20%；Effectively：Reduced rate is 10%～20%, invalid：Reduced rate ＜ 10%.
By the validity Further Division of product, then it is divided into significant curative effect：Postprandial blood sugar TG-AUC reduced rate >=
20%；Effectively：Reduced rate is 10%～20%, invalid：Reduced rate ＜ 10%.
Area under the curve of blood glucose=(+0.5 hours blood glucose of 0 hours blood glucose) × 0.5/2+ (2 blood of hours blood glucose+0.5 hour
Sugar) × 1.5/2；
Area under the curve of blood glucose reduced rate %=is (below placebo Area under the curve of blood glucose-experimental group blood glucose curve
Product)/placebo Area under the curve of blood glucose × 100%；
The rate of descent of experiment with computing group Area under the curve of blood glucose.
Result of the test is as shown in table 1：
Table 1
As shown in Table 1, take this hypoglycemic composition, monitor four postprandial blood sugars, according to parallel test, 55%
After patient takes this composition, postprandial blood sugar is substantially reduced, and effectively, this composition drops after the meal 32.1% patient's drop postprandial blood sugar
The efficient of blood sugar has reached 87.1%.
Embodiment 2
(1) prepare the composition for reducing postprandial blood sugar：
In the present embodiment, the composition for reducing postprandial blood sugar mainly includes following component by weight percentage：
5 parts of 12 parts of mulberry-leaf extract, 20 parts of cinnamomum cassia extract, 60 parts of green coffee bean extract and excipient；
Wherein, the mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is 3:5:15, the mulberry
In leaf extract, the content of 1-DNJ is 30%, and in the cinnamomum cassia extract, the content of polyphenols is 80%,
The content of the green coffee bean extract Content of Chlorogenic Acid is 10%, and the excipient is isomalt, D-mannital, shallow lake
Powder, dextrin and microcrystalline cellulose.
(2) efficacy validation：
Patient data：Patient 50, the wherein male sex 34, women 21, age distribution is 30-50 year.
, with embodiment 1, experimental result is as shown in table 2 below for remaining diagnostic criteria, instructions of taking, efficacy assessments：
Table 2
As shown in Table 2, take this hypoglycemic composition, monitor four postprandial blood sugars, according to parallel test, 30%
After patient takes this composition, postprandial blood sugar is substantially reduced, and effectively, this composition drops after the meal 40.5% patient's drop postprandial blood sugar
The efficient of blood sugar has reached 70.5%.
Embodiment 3
(1) prepare the composition for reducing postprandial blood sugar：
In the present embodiment, the composition for reducing postprandial blood sugar mainly includes following component by weight percentage：
100 parts of 8 parts of mulberry-leaf extract, 1 part of cinnamomum cassia extract, 5 parts of green coffee bean extract and excipient；
Wherein, the mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is 8:1:5, the mulberry
In leaf extract, the content of 1-DNJ is 0.5%, and in the cinnamomum cassia extract, the content of polyphenols is 1%,
The content of the green coffee bean extract Content of Chlorogenic Acid is 80%, and the excipient is xylitol, D-sorbite and different malt ketone
Sugar alcohol.
(2) efficacy validation：
Patient data：Patient 58, the wherein male sex 35, women 23, age distribution is 30-50 year.
, with embodiment 1, experimental result is as shown in table 3 below for remaining diagnostic criteria, instructions of taking, efficacy assessments：
Table 3
As shown in Table 3, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 41.4% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 33.6% patient's drop postprandial blood sugar
To 75%.
Embodiment 4
(1) prepare the composition for reducing postprandial blood sugar：
In the present embodiment, the composition for reducing postprandial blood sugar mainly includes following component by weight percentage：
50 parts of mulberry-leaf extract, 30 parts of cinnamomum cassia extract, 50 parts of green coffee bean extract and excipient 5-100 parts；
Wherein, the mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is 5:3:5, the mulberry
In leaf extract, the content of 1-DNJ is 25%, and in the cinnamomum cassia extract, the content of polyphenols is 36%,
The content of the green coffee bean extract Content of Chlorogenic Acid is 42%, and the excipient is starch, dextrin, microcrystalline cellulose and carboxylic first
Base sodium cellulosate.
(2) efficacy validation：
Patient data：Patient 50, the wherein male sex 24, women 31, age distribution is 30-50 year.
, with embodiment 1, experimental result is as shown in table 4 below for remaining diagnostic criteria, instructions of taking, efficacy assessments：
Table 4
As shown in Table 4, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 40.5% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 36% patient's drop postprandial blood sugar
76.5%.
Embodiment 5
(1) prepare the composition for reducing postprandial blood sugar：
In the present embodiment, the composition for reducing postprandial blood sugar mainly includes following component by weight percentage：
24 parts of mulberry-leaf extract, 24 parts of cinnamomum cassia extract, 60 parts of green coffee bean extract and excipient 5-100 parts；
Wherein, the mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is 4:4:10, the mulberry
In leaf extract, the content of 1-DNJ is 10%, and in the cinnamomum cassia extract, the content of polyphenols is 30%,
The content of the green coffee bean extract Content of Chlorogenic Acid is 40%, and the excipient is starch, dextrin, microcrystalline cellulose and carboxylic first
Base sodium cellulosate.
(2) efficacy validation：
Patient data：Patient 55, the wherein male sex 24, women 31, age distribution is 30-50 year.
, with embodiment 1, experimental result is as shown in table 5 below for remaining diagnostic criteria, instructions of taking, efficacy assessments：
Table 5
As shown in Table 5, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 51.8% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 30.5% patient's drop postprandial blood sugar
To 82.3%.
Embodiment 6
(1) prepare the composition for reducing postprandial blood sugar：
In the present embodiment, the composition for reducing postprandial blood sugar mainly includes following component by weight percentage：
36 parts of mulberry-leaf extract, 18 parts of cinnamomum cassia extract, 42 parts of green coffee bean extract and excipient 5-100 parts；
Wherein, the mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is 6:3:7, the mulberry
In leaf extract, the content of 1-DNJ is 5%, and in the cinnamomum cassia extract, the content of polyphenols is 45%, institute
The content for stating green coffee bean extract Content of Chlorogenic Acid is 55%, and the excipient is microcrystalline cellulose, sodium carboxymethylcellulose, hydroxyl
Propyl methocel and pulullan polysaccharide.
(2) efficacy validation：
Patient data：Patient 56, the wherein male sex 24, women 32, age distribution is 30-50 year.
, with embodiment 1, experimental result is as shown in table 6 below for remaining diagnostic criteria, instructions of taking, efficacy assessments：
Table 6
As shown in Table 6, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 52.2% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 32.6% patient's drop postprandial blood sugar
To 84.8%.
Comparative example 1
The comparative example the difference is that only that with embodiment 1 do not contain mulberry-leaf extract, excipient is 65 parts, except this
Outside, remaining raw material is same as Example 1 with raw material dosage and efficacy validation, as a result as shown in table 7：
Table 7
As shown in Table 7, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 24.2% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 22.5% patient's drop postprandial blood sugar
To 46.7%.
Comparative example 2
The comparative example the difference is that only with embodiment 1, does not contain cinnamomum cassia extract, 44 parts of excipient, except this it
Outward, remaining raw material is same as Example 1 with raw material dosage and efficacy validation, as a result as shown in table 8：
Table 8
As shown in Table 8, this drop postprandial blood sugar composition is taken, four postprandial blood sugars are monitored, 29.2% patient takes this
After composition, postprandial blood sugar is substantially reduced, and effectively, the effective of postprandial blood sugar drops to 22.5% patient's drop postprandial blood sugar in this composition
Rate has reached 51.7%.
Comparative example 3
The comparative example the difference is that only with embodiment 1, does not contain coffee bean extract, 79 parts of excipient, except this
Outside, remaining raw material is same as Example 1 with raw material dosage and efficacy validation, as a result as shown in table 9：
Table 9
As shown in Table 9, this drop postprandial blood sugar composition is taken, four postprandial blood sugars are monitored, 25.8% patient takes this
After composition, postprandial blood sugar is substantially reduced, and effectively, the effective of postprandial blood sugar drops to 19.2% patient's drop postprandial blood sugar in this composition
Rate has reached 45%.
Comparative example 4
The comparative example the difference is that only with embodiment 1,2 parts of the mulberry-leaf extract, 6 parts of cinnamomum cassia extract, green
3 parts of coffee bean extract, the mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is 2:6:3, except this
Outside, remaining raw material is same as Example 1 with raw material dosage and efficacy validation, as a result as shown in table 10：
Table 10
As shown in Table 10, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 21.2% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 23.3% patient's drop postprandial blood sugar
To 44.5%.
Comparative example 5
The comparative example the difference is that only with embodiment 1,55 parts of the mulberry-leaf extract, 44 parts of cinnamomum cassia extract,
99 parts of green coffee bean extract, the mass ratio of the mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract is 10:8:
18, in addition, remaining raw material is same as Example 1 with raw material dosage and efficacy validation, as a result as shown in table 11：
Table 11
As shown in Table 11, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 17.9% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 20% patient's drop postprandial blood sugar
37.9%.
Comparative example 6
The comparative example the difference is that only with embodiment 1,60 parts of the mulberry-leaf extract, 24 parts of cinnamomum cassia extract,
84 parts of green coffee bean extract, in addition, remaining raw material is same as Example 1 with raw material dosage and efficacy validation, knot
Fruit is as shown in table 12：
Table 12
As shown in Table 12, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 19.6% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 21.3% patient's drop postprandial blood sugar
To 40.9%.
Comparative example 7
The comparative example the difference is that only with embodiment 1,50 parts of the mulberry-leaf extract, 20 parts of cinnamomum cassia extract,
70 parts of green coffee bean extract, in addition, remaining raw material is same as Example 1 with raw material dosage and efficacy validation, knot
Fruit is as shown in table 13：
Table 13
As shown in Table 13, this hypoglycemic composition is taken, four postprandial blood sugars are monitored, 21.7% patient takes this combination
After thing, postprandial blood sugar is substantially reduced, and effectively, this composition drop the efficient of postprandial blood sugar reaches 22.1% patient's drop postprandial blood sugar
To 43.8%.
In sum, from embodiment 1-6 can be seen that hypoglycemic composition of the present invention reduce postprandial blood sugar effect it is bright
Aobvious, after more than 30% patient takes this composition, postprandial blood sugar is substantially reduced, and more than 40.5% patient's drop postprandial blood sugar has
Effect, this composition drop the efficient of postprandial blood sugar have reached more than 70.5%, compared to embodiment 2-3, the mulberry leaf are extracted
The mass ratio of thing, cinnamomum cassia extract and green coffee bean extract is controlled at (4-6):(2-4):(6-10), implement compared to other
Example can further improve the hypoglycemic effect of drop.The group for changing this drop postprandial blood sugar composition is can be seen that from comparative example 1-7
Point, lack any one in mulberry-leaf extract, cinnamomum cassia extract and green coffee bean extract, or change mulberry-leaf extract,
The mass ratio of cinnamomum cassia extract and green coffee bean extract, hypoglycemic effect are decreased obviously, hence it is evident that effectively patient is reduced to
Less than 17.9%, effective patient is reduced to less than 20%, efficient to be reduced to less than 37.9%.It can be seen that, mulberry leaf are extracted
Thing, cinnamomum cassia extract and green coffee bean extract, three kinds of component scientific compatibilities, synergy, reasonably combined excipient, Cai Nengda
The effect of blood sugar is effectively reduced to the present invention.
Applicant states that the present invention illustrates the present invention by above-described embodiment, but the invention is not limited in above-mentioned reality
Example is applied, that is, does not mean that the present invention has to rely on above-described embodiment and could implement.Person of ordinary skill in the field should be bright
, any improvement in the present invention, the addition, concrete mode to the equivalence replacement and auxiliary element of each raw material of product of the present invention
Select etc., within the scope of all falling within protection scope of the present invention and disclosure.
Claims (10)
1. it is a kind of to drop hypoglycemic composition, it is characterised in that the composition mainly includes following component by weight：Mulberry
Leaf extract 8-50 parts, cinnamomum cassia extract 1-30 parts and green coffee bean extract 5-60 parts.
2. composition according to claim 1, it is characterised in that the composition mainly includes by weight such as the following group
Point：Mulberry-leaf extract 20-45 parts, cinnamomum cassia extract 5-25 parts and green coffee bean extract 15-58 parts；
Preferably, the composition mainly includes following component by weight：Mulberry-leaf extract 30-40 parts, cinnamomum cassia extract
10-20 parts and green coffee bean extract 20-50 parts.
3. composition according to claim 1 and 2, it is characterised in that the mulberry-leaf extract, cinnamomum cassia extract and green coffee
The mass ratio of coffee beans extract is (3-8):(1-5):(5-15), preferably (4-6):(2-4):(6-10).
4. the composition according to any one of claim 1-3, it is characterised in that 1- deoxidations are wild in the mulberry-leaf extract
The content of buttocks mycin is 0.5-30%, preferably 1-10%；
Preferably, in the cinnamomum cassia extract, the content of polyphenols is 1-80%, preferably 10-70%.
5. the composition according to any one of claim 1-4, it is characterised in that containing in the green coffee bean extract
Measure as 10-80%, preferably 20-70%.
6. the composition according to any one of claim 1-5, it is characterised in that the composition also includes excipient；
Preferably, the excipient be filler, lubricant, disintegrant, colouring agent or flavouring in any one or at least
Two kinds of mixture；
Preferably, the excipient is xylitol, D-sorbite, isomalt, D-mannital, starch, dextrin, crystallite
It is cellulose, sodium carboxymethylcellulose, hydroxypropyl methyl cellulose, pulullan polysaccharide, talcum powder, superfine silica gel powder, magnesium stearate, hard
In resin acid calcium or ethanol any one or at least two mixing.
7. the composition according to any one of claim 1-6, it is characterised in that the parts by weight of the excipient account for institute
State 5-100 parts of composition, preferably 10-80 parts.
8. it is a kind of to drop hypoglycemic medicine, it is characterised in that the medicine includes the combination any one of claim 1-8
Thing；
Preferably, the formulation of the medicine is any one in tablet, capsule or granule or at least two combination.
9. a kind of hypoglycemic composition of drop as any one of claim 1-7 or reduction as claimed in claim 8
The medicine of blood sugar is used to improve IGT.
10. a kind of hypoglycemic composition of drop as any one of claim 1-7 or reduction as claimed in claim 8
The medicine of blood sugar is used to treat type-II diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611108062.XA CN106511544A (en) | 2016-12-06 | 2016-12-06 | Composition for reducing blood glucose and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611108062.XA CN106511544A (en) | 2016-12-06 | 2016-12-06 | Composition for reducing blood glucose and application of composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511544A true CN106511544A (en) | 2017-03-22 |
Family
ID=58341438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611108062.XA Pending CN106511544A (en) | 2016-12-06 | 2016-12-06 | Composition for reducing blood glucose and application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511544A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112190627A (en) * | 2020-11-03 | 2021-01-08 | 广东南方医大科技开发有限公司 | Traditional Chinese medicine composition for treating type 2 diabetes and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127231A (en) * | 2011-12-02 | 2013-06-05 | 苏州法莫生物技术有限公司 | Chinese medicine for diabetes treatment |
| CN105960171A (en) * | 2014-06-13 | 2016-09-21 | 帕万·库马·戈埃尔 | Green coffee bean extract and method thereof |
| CN105941780A (en) * | 2016-07-06 | 2016-09-21 | 慧谷生命科技湖北有限公司 | Green coffee solid drink and preparation method thereof |
-
2016
- 2016-12-06 CN CN201611108062.XA patent/CN106511544A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127231A (en) * | 2011-12-02 | 2013-06-05 | 苏州法莫生物技术有限公司 | Chinese medicine for diabetes treatment |
| CN105960171A (en) * | 2014-06-13 | 2016-09-21 | 帕万·库马·戈埃尔 | Green coffee bean extract and method thereof |
| CN105941780A (en) * | 2016-07-06 | 2016-09-21 | 慧谷生命科技湖北有限公司 | Green coffee solid drink and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112190627A (en) * | 2020-11-03 | 2021-01-08 | 广东南方医大科技开发有限公司 | Traditional Chinese medicine composition for treating type 2 diabetes and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104256632B (en) | A kind of health product improving sleep | |
| CN106360310A (en) | Composition for dropping after meal blood sugar and application thereof | |
| CN101450166A (en) | Traditional Chinese medicine composition with blood-sugar function and preparation method thereof | |
| HUE029291T2 (en) | Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy | |
| JP2012207009A (en) | Method for producing mulberry twig pulverized powder | |
| US10894070B2 (en) | Drug compound for the control of blood glucose, blood lipids and weight | |
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN102948749A (en) | American ginseng and omei mountain kudzuvine capsule | |
| Shane-McWhorter | Botanical dietary supplements and the treatment of diabetes: what is the evidence? | |
| CN103653148B (en) | Guava leaf liquid beverage | |
| CN101606703A (en) | A kind of nutraceutical and preparation method thereof with antihypertensive function | |
| CN105079494A (en) | Dendrobium officinale capsule for lowering blood sugar and preparation method of dendrobium officinale capsule | |
| CN109123351A (en) | A kind of special doctor's food and preparation method with hyperglycemia population generation meal regulatory function | |
| CN112971154A (en) | Solid mixture rich in water-soluble dietary fibers and alpha-amylase inhibitor, and preparation method and application thereof | |
| CN106511544A (en) | Composition for reducing blood glucose and application of composition | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| CN102266391A (en) | Composition extracted from medicinal and edible plants and able to adjust fasting and postprandial blood glucose simultaneously | |
| CN102614359B (en) | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof | |
| CN104644734A (en) | Drug for treating type II diabetes and complications thereof | |
| CN104256618B (en) | A kind of hypoglycemic food, health products or pharmaceutical composition | |
| CN101829194B (en) | Composition for curing II-type diabetes mellitus and preparation method thereof | |
| CN104758772A (en) | Japanese galangal flower extract for improving sugar tolerance and usage of Japanese galangal flower extract | |
| CN101406642A (en) | Antihypelipidemic compound formulation | |
| CN109528927A (en) | The Chinese medicine for treating diabetes | |
| CN108853354A (en) | For qi-blood deficiency and beautifying face and moistering lotion composition and preparation method and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170606 Address after: 102200 Beijing science and Technology Park of Changping District Bai Fu Road 13 Applicant after: BEIJING ZHI FENG TANG HEALTH TECHNOLOGY CO., LTD. Address before: Room 100020, building 12, No. 93 Jianguo Road, Beijing, Chaoyang District, China, 1602.1603 Applicant before: Sugar Butler (Beijing) Health Management Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190108 Address after: Room 1602 and 1603, Building 12, 93 Jianguo Road, Chaoyang District, Beijing Applicant after: Sugar Butler (Beijing) Health Management Co., Ltd. Address before: 102200 No. 13 Baifuquan Road, Changping District Science Park, Beijing Applicant before: Beijing Zhifengtang Health Science and Technology Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
| RJ01 | Rejection of invention patent application after publication |